Galiximab

Summary

Galiximab (CHEMBL2109191) is a phase-3 clinical-stage antibody; indicated across 2 conditions including lymphoma and non-hodgkin lymphoma; with CIViC clinical evidence for 1 variant-indication association (e.g. CD80 Overexpression in b-cell non-hodgkin lymphoma).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 5
• Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109191
Name	Galiximab
Type	Antibody
Max phase	3

Also known as: Galiximab, IDEC-114, GALIXIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lymphoma	3	MONDO:0005062	EFO:0000574
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00048555	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin’s Lymphoma
NCT00117975	PHASE2	COMPLETED	Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin’s Lymphoma
NCT00516217	PHASE2	COMPLETED	Galiximab in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma
NCT00575068	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin’s Lymphoma
NCT00651443	PHASE1	TERMINATED	Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin’s Lymphoma

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
CD80 Overexpression	B-cell Non-Hodgkin Lymphoma	Sensitivity/Response	Cisplatin + Galiximab	CIViC D	EID12554

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).